A New Hair-Loss Pill Just Passed a Major Test With an 80% Success Rate

For nearly 30 years, if you wanted to keep your hair from making a break for it, your options were pretty much limited. But now, a new oral medication called VDPHL01 is strutting onto the scene, and it just passed a critical clinical trial with some seriously impressive numbers.

Developed by Veradermics, this pill could be the first new effective hair-loss drug in the US since the Clinton administration. Which, if you think about it, is a long time for a problem that affects roughly 80 million adults.

Dr. Maryanne Makredes Senna, a Harvard Medical School professor and advisor to Veradermics, is calling it a potential game-changer. Why? Because nearly 80% of patients and investigators in the trial saw improvement. Let that satisfying number sink in.

The Numbers Don't Lie

The study enrolled 519 men, and the results were more than just promising. Volunteers taking one daily dose of VDPHL01 reported better hair coverage in 79.3% of cases, while those taking two doses saw an 86% improvement. For comparison, the placebo group only managed a 35.6% bump. (Which, honestly, is still better than zero, but we digress.)

After six months, the two-a-day dose group grew an average of 33 hairs per square centimeter. The placebo group? A meager 7.3 hairs. And the best part? The drug was well-tolerated, meaning patients weren't bailing on it due to side effects. The dropout rates were similar for both the drug and placebo groups, which is exactly what you want to see.

What makes VDPHL01 particularly interesting is that it's an extended-release minoxidil tablet. Minoxidil, you might recall, is the active ingredient in many topical hair growth treatments. But this oral version is designed to maximize hair restoration while minimizing those pesky heart-related risks sometimes associated with minoxidil.

If it gets the green light, VDPHL01 would be the first non-hormonal pill for pattern hair loss to earn FDA approval. Which is a big deal, considering the existing options often come with hormonal considerations.

What's Next on the Horizon?

With these positive Phase III results in the bag, everyone's now watching for the second male trial, Study 304, with results expected in late 2026. Because apparently that's where we are now: waiting on hair growth data for 2026. The company has also kicked off a trial for women with pattern hair loss, aptly named Study 306.

So, while the world isn't quite ready to declare male pattern baldness a thing of the past, VDPHL01 is certainly making a strong case for a future where your hair stays put. Or at least, makes a valiant effort.